You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Impact of oncogene rearrangement patterns on outcomes in patients with double‐hit non‐Hodgkin lymphoma
|
|---|---|
| Published in |
Cancer (0008543X), November 2015
|
| DOI | 10.1002/cncr.29781 |
| Pubmed ID | |
| Authors |
Daniel J Landsburg, Adam M Petrich, Jeremy S Abramson, Aliyah R Sohani, Oliver Press, Ryan Cassaday, Julio C Chavez, Kevin Song, Andrew D Zelenetz, Mitul Gandhi, Namrata Shah, Timothy S Fenske, Jesse Jaso, L Jeffrey Medeiros, David T Yang, Chadi Nabhan |
| Abstract |
Double-hit lymphomas (DHLs) are collectively defined as B-cell non-Hodgkin lymphomas harboring rearrangements of MYC as well as B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6). To the authors' knowledge, the impact of specific oncogene rearrangements on outcomes of patients with DHL who are treated with immunochemotherapy has not been previously described. The authors identified patients whose diagnostic tissue specimens underwent metaphase karyotyping or fluorescence in situ hybridization for MYC as well as both BCL2 and BCL6 rearrangements. Cohorts were defined by the presence (+) or absence (-) of rearrangements: MYC+/BCL2+/BCL6- (BCL2-DHL), MYC+/BCL2-/BCL6+ (BCL6-DHL), and MYC+/BCL2+/BCL6+ (triple-hit lymphoma; THL). A total of 117 patients were included in the current analysis (76 BCL2-DHL patients, 16 BCL6-DHL patients, and 25 THL patients). Compared with patients with BCL2-DHL, those with BCL6-DHL were more likely to be classified as having a non-germinal center cell of origin, presented with extranodal disease, and appeared to achieve higher rates of complete response despite receiving intensive induction therapy less frequently. However, patients with BCL6-DHL experienced a shorter median overall survival if achieving an initial complete response compared with patients with BCL2-DHL. Patients with THL experienced survival outcomes similar to those of patients with BCL2-DHL. Recognition of the specific oncogene rearrangements may be of prognostic value and potentially guide future therapeutic strategies for patients with DHL. Cancer 2015. © 2015 American Cancer Society. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 8 | 80% |
| Australia | 1 | 10% |
| Unknown | 1 | 10% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 40% |
| Scientists | 3 | 30% |
| Practitioners (doctors, other healthcare professionals) | 2 | 20% |
| Science communicators (journalists, bloggers, editors) | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Unknown | 74 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 15% |
| Student > Doctoral Student | 10 | 13% |
| Student > Bachelor | 10 | 13% |
| Other | 7 | 9% |
| Student > Ph. D. Student | 7 | 9% |
| Other | 17 | 23% |
| Unknown | 13 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 56% |
| Biochemistry, Genetics and Molecular Biology | 9 | 12% |
| Business, Management and Accounting | 3 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Nursing and Health Professions | 2 | 3% |
| Other | 3 | 4% |
| Unknown | 14 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 August 2022.
All research outputs
#3,289,495
of 25,460,914 outputs
Outputs from Cancer (0008543X)
#2,764
of 14,113 outputs
Outputs of similar age
#43,536
of 292,473 outputs
Outputs of similar age from Cancer (0008543X)
#43
of 123 outputs
Altmetric has tracked 25,460,914 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 14,113 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 292,473 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 123 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.